ArticleFrontiers in medicine2026
Pragmatic evaluation of prescription glucosamine sulfate (pGS) in knee osteoarthritis: insights from a Filipino cohort.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The real-world effectiveness and tolerability of prescription glucosamine sulfate (pGS) in reducing knee osteoarthritis (KOA) symptoms in a Filipino cohort was evaluated. Methods: This 8-week, pragmatic, open-label, multicenter study enrolled 281 Filipino adults with mild-to-moderate (Kellgren-Lawrence grade 2-3) KOA. Participants received pGS 1,500 mg once daily. Outcomes included changes from baseline assessed with the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and Visual Analog Scale (VAS) for pain at Weeks 4, 6, and 8. Tolerability was evaluated through adverse event monitoring. Results: Among 281 treated patients, 277 (98.6%) completed the study, and 245 (~88.0%) received pGS alone for the full period. These patients demonstrated rapid, sustained symptom improvement, with knee pain decreasing by Week 4 and continuing through Week 8. After 4 weeks, 132 patients (~47.0%) had already achieved ≥50.0% pain reduction. By Week 8, WOMAC pain showed a least squares (LS) mean change of -11.96 (95% CI: -12.26 to -11.67), with marked improvements in stiffness, physical function, and total score. VAS pain decreased from 68.4 mm at baseline to 11.9 mm at Week 8, consistent with meaningful clinical benefit. Treatment satisfaction was high, with 98.78% satisfied at Week 8 and a mean psychometric VAS score of 9.0. Patients with more advanced KOA requiring add-on therapy ( Conclusion: Prescription glucosamine sulfate improved pain, stiffness, and function in Filipino patients with mild-to-moderate KOA as early as Week 4, sustained through Week 8. Treatment was well tolerated, with high satisfaction and one discontinuation. Most patients (~88%) were effectively managed with pGS monotherapy, while add-on celecoxib benefited those with insufficient response, supporting a multimodal approach for KOA symptom control in routine care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.